TD Private Client Wealth LLC Reduces Stock Position in Sanofi (NASDAQ:SNY)

TD Private Client Wealth LLC lowered its stake in Sanofi (NASDAQ:SNY) by 8.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,033 shares of the company’s stock after selling 8,763 shares during the quarter. TD Private Client Wealth LLC’s holdings in Sanofi were worth $4,487,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Lee Danner & Bass Inc. bought a new position in Sanofi in the fourth quarter worth approximately $31,000. DCF Advisers LLC raised its position in Sanofi by 31.8% in the fourth quarter. DCF Advisers LLC now owns 14,500 shares of the company’s stock worth $699,000 after acquiring an additional 3,500 shares during the period. Magnetar Financial LLC raised its position in Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after acquiring an additional 1,705,148 shares during the period. Stokes Family Office LLC bought a new position in Sanofi in the fourth quarter worth approximately $465,000. Finally, ProVise Management Group LLC raised its position in Sanofi by 0.4% in the fourth quarter. ProVise Management Group LLC now owns 187,427 shares of the company’s stock worth $9,040,000 after acquiring an additional 733 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on SNY. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday. They set a “neutral” rating and a $65.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Stock Performance

SNY opened at $56.90 on Friday. The stock has a market capitalization of $144.40 billion, a price-to-earnings ratio of 22.85, a PEG ratio of 1.01 and a beta of 0.58. The company has a fifty day moving average of $54.55 and a 200 day moving average of $52.93. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.